TTY Biopharm Co Ltd (4105) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.097x

Based on the latest financial reports, TTY Biopharm Co Ltd (4105) has a cash flow conversion efficiency ratio of 0.097x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$778.89 Million ≈ $24.54 Million USD) by net assets (NT$8.05 Billion ≈ $253.66 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See TTY Biopharm Co Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

TTY Biopharm Co Ltd - Cash Flow Conversion Efficiency Trend (2017–2025)

This chart illustrates how TTY Biopharm Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

TTY Biopharm Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TTY Biopharm Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Shenzhen King Explorer Science and Technology Corp Class A SHE:002917	0.035x
Sparebank 1 Ostfold Akershus OL:SOAG	0.060x
Shenzhen Guangju Energy Co Ltd SHE:000096	0.003x
N-Able Inc NYSE:NABL	0.022x
Oeneo SA PA:SBT	0.044x
Luoyang Glass SHG:600876	0.003x
Shanghai Jin Jiang International Industrial Investment Co Ltd A SHG:600650	0.032x
Jinneng Science&Tech Co Ltd SHG:603113	-0.049x

Annual Cash Flow Conversion Efficiency for TTY Biopharm Co Ltd (2017–2025)

The table below shows the annual cash flow conversion efficiency of TTY Biopharm Co Ltd from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of TTY Biopharm Co Ltd.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	NT$8.05 Billion ≈ $253.66 Million	NT$1.76 Billion ≈ $55.51 Million	0.219x	+21.80%
2024-12-31	NT$7.51 Billion ≈ $236.64 Million	NT$1.35 Billion ≈ $42.51 Million	0.180x	+7.70%
2023-12-31	NT$6.51 Billion ≈ $204.98 Million	NT$1.09 Billion ≈ $34.19 Million	0.167x	-15.86%
2022-12-31	NT$6.23 Billion ≈ $196.38 Million	NT$1.24 Billion ≈ $38.93 Million	0.198x	-8.99%
2021-12-31	NT$5.77 Billion ≈ $181.70 Million	NT$1.26 Billion ≈ $39.58 Million	0.218x	+151.55%
2020-12-31	NT$6.08 Billion ≈ $191.49 Million	NT$526.35 Million ≈ $16.58 Million	0.087x	-55.84%
2019-12-31	NT$6.17 Billion ≈ $194.36 Million	NT$1.21 Billion ≈ $38.12 Million	0.196x	+16.74%
2018-12-31	NT$6.39 Billion ≈ $201.37 Million	NT$1.07 Billion ≈ $33.83 Million	0.168x	+3.03%
2017-12-31	NT$6.11 Billion ≈ $192.55 Million	NT$996.52 Million ≈ $31.40 Million	0.163x	--

About TTY Biopharm Co Ltd

TWO:4105 Taiwan Drug Manufacturers - Specialty & Generic

Market Cap

$575.79 Million

NT$18.28 Billion TWD

Market Cap Rank

#11650 Global

#441 in Taiwan

Share Price

NT$73.50

Change (1 day)

-0.27%

52-Week Range

NT$72.10 - NT$86.30

All Time High

NT$97.91